Well-designed clinical trials with depression as a primary outcome measure are needed to establish whether GLP-1 agonists have genuine antidepressant properties independent of their metabolic effects
McIlveen and Alyssa Jastrzebski monitor your B12 levels as part of your primary care
GLP-1 medications reduce overall hunger but don't eliminate sweet cravings on GLP-1 for most people
Clin Neurol Neurosurg 108:794797 Schols L, Zange J, Abele M, Schillings M, Skipka G, Kuntz-Hehner S, van Beekvelt MC, Colier WN, Muller K, Klockgether T, Przuntek H, Vorgerd M (2005) l-Carnitine and creatine in Friedreichs ataxia
Knowing what your specific plan does right now is what actually saves you money
doi: 10.3389/fimmu.2026.1845654 Received 02 April 2026 Revised 07 April 2026 Accepted 21 April 2026 Published 11 May 2026 Volume 17 - 2026 Edited by Venkata Ramireddy Narala, Yogi Vemana University, India Reviewed by Farrah Kheradmand, Baylor College of Medicine, United States Homayon Ghiasi, Cedars Sinai Medical Center, United States Updates Copyright 2026 Cain, Hurrell, Shen, Speliakos and Akbari
